Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: bio_kruncher who wrote (25911)	2/21/2008 12:48:39 PM
From: Biomaven	Respond to of 52153

Here's a PR from Chemokine Therapeutics on some preclinical stuff - as you said, focused on CXCR4 (with a peptide analog antagonist): Press Release Source: Chemokine Therapeutics Corp. Chemokine Therapeutics Announces Three Abstracts Accepted for Presentation at the AACR Annual Meeting on its Lead Drug Candidate CTCE-9908 Thursday February 21, 8:45 am ET VANCOUVER, BRITISH COLUMBIA--(MARKET WIRE)--Feb 21, 2008 -- Chemokine Therapeutics Corp. (the "Company") (Toronto:CTI.TO - News)(OTC BB:CHKT.OB - News), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, and vascular diseases, today announced that three abstracts regarding the Company's lead drug candidate CTCE-9908 were accepted by the American Association for Cancer Research ("AACR") for presentation at their Annual Meeting being held in San Diego, California, April 13 - 16, 2008. ADVERTISEMENT The meeting has become the world's largest and most comprehensive gathering of cancer researchers attracting more than 17,000 participants from 60 countries to discuss and hear presentations on new and significant discoveries in basic, clinical, and translational cancer research. The AACR hopes to identify the most compelling science and ensure that the latest advances in all areas of cancer research and specifically the most important emerging research fields are fully covered. The first abstract, titled "Targeting CXCR4 inhibits primary tumor growth and distant metastasis in a transgenic breast cancer mouse model" submitted by Dr. Mark Basik, Department of Oncology, Jewish General Hospital will be presented at the AACR Annual Meeting on Sunday, April 13, 2008 at 1:00pm. A second abstract, titled "A pilot study assessing the utility of cytokines as surrogate endpoints in therapy directed against chemokine mediated metastasis" submitted by Dr. Peter Kavsak, Juravinski Cancer Centre will be presented at the AACR Annual Meeting on Monday, April 14, 2008 at 1:00pm. A third abstract, titled "Blockade of therapy-induced acute recruitment of bone marrow-derived CXCR4+Flt-1+ hemangiocytes inhibits hypoxia-induced tumor angiogenesis in hepatocellular carcinoma" submitted by Dr. Ronnie Poon, Department of Surgery, University of Hong Kong will be presented at the AACR Annual Meeting on Wednesday, April 16, 2008 at 8:00am. Researchers at these prestigious organizations have been studying the ability of CTCE-9908, lead drug candidate from Chemokine Therapeutics, to inhibit growth and metastasis of human cancer in pre-clinical and clinical studies as part of a collaborative research effort with the Company. "Our collaborative research continues to build our understanding that CTCE-9908 is a multi-targeted agent that not only acts to block the metastatic process but in addition has an effect on established disease through its anti-angiogenic properties. The AACR provides an excellent forum to share these important findings with distinguished members of the medical and scientific community," stated Walter Korz, Vice President, Drug Development for the Company. About CTCE-9908 CTCE-9908 is a peptide analog of the chemokine SDF-1, and an antagonist of its receptor, CXCR4. SDF-1 is the only known naturally occurring chemokine that binds to CXCR4, which is present on many cancer cells as well as cancer support cells such as cells making up new blood vessels. This binding process is believed to be critical in the SDF-1 induced cell migration. The anti-migration property of CTCE-9908 is pivotal in not only reducing recruitment of support cells that allow survival and growth of the primary tumor, but also metastasis (or spread) of cancer cells to distant locations in the body, where they form secondary tumors. Approximately 90% of cancer deaths are due to metastasis and disease progression. We believe that CTCE-9908 has the potential to shrink the primary tumor and delay the occurrence of new tumors due to its anti-angiogenic properties and anti-metastatic activity. About Chemokine Therapeutics Corp. (Toronto:CTI.TO - News)(OTC BB:CHKT.OB - News) Chemokine Therapeutics is a product-focused biotechnology company developing drug candidates in the field of chemokines. Chemokines are a class of signaling proteins that play a critical role in the growth, differentiation, and maturation of cells necessary for fighting infection as well as tissue repair and regeneration. Chemokines also have an important role in cancer metastasis and growth. Chemokine Therapeutics is a leader in research in the field of chemokines and has several products in various stages of development.